Loading…

Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes

BACKGROUND: Risedronate (Actonel, Procter & Gamble Pharmaceuticals) is commercially available only as film-coated tablets. Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated. OBJECTIVE: To evaluate procedure...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2005-01, Vol.39 (1), p.63-67
Main Authors: Dansereau, Richard J, Crail, Debbie J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673
cites cdi_FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673
container_end_page 67
container_issue 1
container_start_page 63
container_title The Annals of pharmacotherapy
container_volume 39
creator Dansereau, Richard J
Crail, Debbie J
description BACKGROUND: Risedronate (Actonel, Procter & Gamble Pharmaceuticals) is commercially available only as film-coated tablets. Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated. OBJECTIVE: To evaluate procedures for dissolving risedronate sodium tablets for administration in liquid form and drug recovery following dissolution in cups and following passage through different types of feeding tubes. METHODS: Tablets (5 and 35 mg) were individually dispersed in 2 oz of water. After 2 minutes, the solution was stirred for 30 seconds, dispensed, and rinsed with an additional 4 oz of water. The sample was filtered and analyzed by HPLC. Ten replicates were performed using the various cups. Gastrostomy and nasoenteric tubes were flushed with 1 oz of water. Individual tablets were dispersed in 2 oz of water; after 2 minutes, the solution was stirred for 30 seconds and poured through the tube and flushed with 1 oz of water. Samples were filtered and analyzed by HPLC. Ten replicates were performed for each type of feeding tube. RESULTS: For cups, the mean amount of drug recovered ranged from 95.7% to 100.5% of the label claim, with a relative standard deviation (RSD) range of 1.1–6.3%. For gastrostomy and nasoenteric tubes, the mean amount of drug recovered ranged from 98.3% to 101.9% of label claim, with an RSD range of 0.9–3.3%. CONCLUSIONS: A simple and accurate procedure was developed for dissolving risedronate tablets in water to prepare a liquid formulation for administration orally or through feeding tubes.
doi_str_mv 10.1345/aph.1E299
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67333201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1E299</sage_id><sourcerecordid>67333201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673</originalsourceid><addsrcrecordid>eNptkE1v1DAQQCMEoqVw4A-gHKASh5SxHTvxsSpbQKpUhJaz5SSTXa-cePEkXfj3dZuV9sJpRpo3Xy_L3jO4YqKUX-x-e8VWXOsX2TmTJS8Ur-BlykFBAbyGs-wN0Q4ANOP6dXbGpNRQV_I8263-TjjsQ7QjhpnynzG02M0RKe9DzL86ouAf3LjJfznCLobRTpivbeNxWpD7aH1-3Q1udDRFO7kw5nbsnmu3iN1T73pukN5mr3rrCd8d40X2-3a1vvle3N1_-3FzfVe0ohJTYXurdc8kU5xZFE2rGqilFghaNSrdXem6AdYj1KwCwJJBzUveyIpBWalKXGSXy9x9DH9mpMkMjlr0fnnRJEQIDiyBnxewjYEoYm_20Q02_jMMzJNYk8SaZ7GJ_XAcOjcDdifyaDIBn46Apdb6PgltHZ04JWupND9dR3aDZhfmOCYZ_934cQG3brM9uIiGBut92s_M4XAQ2jCjhHgEl-WZqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67333201</pqid></control><display><type>article</type><title>Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes</title><source>Sage Journals Online</source><creator>Dansereau, Richard J ; Crail, Debbie J</creator><creatorcontrib>Dansereau, Richard J ; Crail, Debbie J</creatorcontrib><description>BACKGROUND: Risedronate (Actonel, Procter &amp; Gamble Pharmaceuticals) is commercially available only as film-coated tablets. Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated. OBJECTIVE: To evaluate procedures for dissolving risedronate sodium tablets for administration in liquid form and drug recovery following dissolution in cups and following passage through different types of feeding tubes. METHODS: Tablets (5 and 35 mg) were individually dispersed in 2 oz of water. After 2 minutes, the solution was stirred for 30 seconds, dispensed, and rinsed with an additional 4 oz of water. The sample was filtered and analyzed by HPLC. Ten replicates were performed using the various cups. Gastrostomy and nasoenteric tubes were flushed with 1 oz of water. Individual tablets were dispersed in 2 oz of water; after 2 minutes, the solution was stirred for 30 seconds and poured through the tube and flushed with 1 oz of water. Samples were filtered and analyzed by HPLC. Ten replicates were performed for each type of feeding tube. RESULTS: For cups, the mean amount of drug recovered ranged from 95.7% to 100.5% of the label claim, with a relative standard deviation (RSD) range of 1.1–6.3%. For gastrostomy and nasoenteric tubes, the mean amount of drug recovered ranged from 98.3% to 101.9% of label claim, with an RSD range of 0.9–3.3%. CONCLUSIONS: A simple and accurate procedure was developed for dissolving risedronate tablets in water to prepare a liquid formulation for administration orally or through feeding tubes.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1E299</identifier><identifier>PMID: 15590875</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Administration, Oral ; Biological and medical sciences ; Chemistry, Pharmaceutical ; Drug Compounding ; Enteral Nutrition ; Etidronic Acid - administration &amp; dosage ; Etidronic Acid - analogs &amp; derivatives ; Etidronic Acid - chemistry ; General pharmacology ; Medical sciences ; Pharmaceutical Solutions ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Risedronate Sodium ; Solubility ; Tablets - chemistry</subject><ispartof>The Annals of pharmacotherapy, 2005-01, Vol.39 (1), p.63-67</ispartof><rights>2005 SAGE Publications</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673</citedby><cites>FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925,79236</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16585692$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15590875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dansereau, Richard J</creatorcontrib><creatorcontrib>Crail, Debbie J</creatorcontrib><title>Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>BACKGROUND: Risedronate (Actonel, Procter &amp; Gamble Pharmaceuticals) is commercially available only as film-coated tablets. Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated. OBJECTIVE: To evaluate procedures for dissolving risedronate sodium tablets for administration in liquid form and drug recovery following dissolution in cups and following passage through different types of feeding tubes. METHODS: Tablets (5 and 35 mg) were individually dispersed in 2 oz of water. After 2 minutes, the solution was stirred for 30 seconds, dispensed, and rinsed with an additional 4 oz of water. The sample was filtered and analyzed by HPLC. Ten replicates were performed using the various cups. Gastrostomy and nasoenteric tubes were flushed with 1 oz of water. Individual tablets were dispersed in 2 oz of water; after 2 minutes, the solution was stirred for 30 seconds and poured through the tube and flushed with 1 oz of water. Samples were filtered and analyzed by HPLC. Ten replicates were performed for each type of feeding tube. RESULTS: For cups, the mean amount of drug recovered ranged from 95.7% to 100.5% of the label claim, with a relative standard deviation (RSD) range of 1.1–6.3%. For gastrostomy and nasoenteric tubes, the mean amount of drug recovered ranged from 98.3% to 101.9% of label claim, with an RSD range of 0.9–3.3%. CONCLUSIONS: A simple and accurate procedure was developed for dissolving risedronate tablets in water to prepare a liquid formulation for administration orally or through feeding tubes.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>Drug Compounding</subject><subject>Enteral Nutrition</subject><subject>Etidronic Acid - administration &amp; dosage</subject><subject>Etidronic Acid - analogs &amp; derivatives</subject><subject>Etidronic Acid - chemistry</subject><subject>General pharmacology</subject><subject>Medical sciences</subject><subject>Pharmaceutical Solutions</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Risedronate Sodium</subject><subject>Solubility</subject><subject>Tablets - chemistry</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNptkE1v1DAQQCMEoqVw4A-gHKASh5SxHTvxsSpbQKpUhJaz5SSTXa-cePEkXfj3dZuV9sJpRpo3Xy_L3jO4YqKUX-x-e8VWXOsX2TmTJS8Ur-BlykFBAbyGs-wN0Q4ANOP6dXbGpNRQV_I8263-TjjsQ7QjhpnynzG02M0RKe9DzL86ouAf3LjJfznCLobRTpivbeNxWpD7aH1-3Q1udDRFO7kw5nbsnmu3iN1T73pukN5mr3rrCd8d40X2-3a1vvle3N1_-3FzfVe0ohJTYXurdc8kU5xZFE2rGqilFghaNSrdXem6AdYj1KwCwJJBzUveyIpBWalKXGSXy9x9DH9mpMkMjlr0fnnRJEQIDiyBnxewjYEoYm_20Q02_jMMzJNYk8SaZ7GJ_XAcOjcDdifyaDIBn46Apdb6PgltHZ04JWupND9dR3aDZhfmOCYZ_934cQG3brM9uIiGBut92s_M4XAQ2jCjhHgEl-WZqw</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Dansereau, Richard J</creator><creator>Crail, Debbie J</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes</title><author>Dansereau, Richard J ; Crail, Debbie J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>Drug Compounding</topic><topic>Enteral Nutrition</topic><topic>Etidronic Acid - administration &amp; dosage</topic><topic>Etidronic Acid - analogs &amp; derivatives</topic><topic>Etidronic Acid - chemistry</topic><topic>General pharmacology</topic><topic>Medical sciences</topic><topic>Pharmaceutical Solutions</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Risedronate Sodium</topic><topic>Solubility</topic><topic>Tablets - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dansereau, Richard J</creatorcontrib><creatorcontrib>Crail, Debbie J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dansereau, Richard J</au><au>Crail, Debbie J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>39</volume><issue>1</issue><spage>63</spage><epage>67</epage><pages>63-67</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>BACKGROUND: Risedronate (Actonel, Procter &amp; Gamble Pharmaceuticals) is commercially available only as film-coated tablets. Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated. OBJECTIVE: To evaluate procedures for dissolving risedronate sodium tablets for administration in liquid form and drug recovery following dissolution in cups and following passage through different types of feeding tubes. METHODS: Tablets (5 and 35 mg) were individually dispersed in 2 oz of water. After 2 minutes, the solution was stirred for 30 seconds, dispensed, and rinsed with an additional 4 oz of water. The sample was filtered and analyzed by HPLC. Ten replicates were performed using the various cups. Gastrostomy and nasoenteric tubes were flushed with 1 oz of water. Individual tablets were dispersed in 2 oz of water; after 2 minutes, the solution was stirred for 30 seconds and poured through the tube and flushed with 1 oz of water. Samples were filtered and analyzed by HPLC. Ten replicates were performed for each type of feeding tube. RESULTS: For cups, the mean amount of drug recovered ranged from 95.7% to 100.5% of the label claim, with a relative standard deviation (RSD) range of 1.1–6.3%. For gastrostomy and nasoenteric tubes, the mean amount of drug recovered ranged from 98.3% to 101.9% of label claim, with an RSD range of 0.9–3.3%. CONCLUSIONS: A simple and accurate procedure was developed for dissolving risedronate tablets in water to prepare a liquid formulation for administration orally or through feeding tubes.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>15590875</pmid><doi>10.1345/aph.1E299</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2005-01, Vol.39 (1), p.63-67
issn 1060-0280
1542-6270
language eng
recordid cdi_proquest_miscellaneous_67333201
source Sage Journals Online
subjects Administration, Oral
Biological and medical sciences
Chemistry, Pharmaceutical
Drug Compounding
Enteral Nutrition
Etidronic Acid - administration & dosage
Etidronic Acid - analogs & derivatives
Etidronic Acid - chemistry
General pharmacology
Medical sciences
Pharmaceutical Solutions
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Risedronate Sodium
Solubility
Tablets - chemistry
title Extemporaneous Procedures for Dissolving Risedronate Tablets for Oral Administration and for Feeding Tubes
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A19%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extemporaneous%20Procedures%20for%20Dissolving%20Risedronate%20Tablets%20for%20Oral%20Administration%20and%20for%20Feeding%20Tubes&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Dansereau,%20Richard%20J&rft.date=2005-01-01&rft.volume=39&rft.issue=1&rft.spage=63&rft.epage=67&rft.pages=63-67&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.1E299&rft_dat=%3Cproquest_cross%3E67333201%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c373t-afa99f151621ae3bc6b08593e096b6590798b01fe081700e4108242b571047673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67333201&rft_id=info:pmid/15590875&rft_sage_id=10.1345_aph.1E299&rfr_iscdi=true